Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Phibro Animal Health appoints Joyce J. Lee as Independent Director

Phibro Animal Health Corporation (Nasdaq: PAHC) has announced the appointment of Joyce J. Lee, MBA, as a Class II director of the company, effective immediately, bringing the total board membership to nine directors, six of whom are independent directors.

Ms. Lee's appointment fills a current vacancy and increases the company's independent director count. She brings a wealth of expertise and leadership, having most recently served as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Ms. Lee's extensive experience includes executive, global, regional, and country-level leadership roles in publicly held companies, and her significant contributions to the animal health industry were recognized in 2018 when she received the prestigious Feather in Her Cap Award.

Phibro Animal Health Corporation is optimistic about working with Ms. Lee, as she has a proven track record of driving value creation for leading brands in the animal health industry, including beef, dairy, swine, and global aquaculture, along with knowledge of the pet care category. Her strategic vision, operational expertise, industry knowledge, and public company governance experience qualify her to serve on the company's Board of Directors.

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company that aims to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals.

Following these announcements, the company's shares moved -0.5%, and are now trading at a price of $21.77. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS